Mesoblast Ltd (ASX:MSB) Share Price

Company Profile

Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUS
T: +61 396396036
E: [email protected]
https://www.mesoblast.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108

Recommended

Morningstar analysts see value in several stocks under fire from shorts.

Lewis Jackson | 12 January 2022

Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.

Emma Rapaport | 15 June 2020

The biotech giant has jumped 22pc a year for the past decade but new players are emerging.

Nicki Bourlioufas | 07 April 2019

Index	Last price	Change	% Change
All Ordinaries	8,921.50	15.50	-0.17%
CAC 40	7,834.14	1.26	0.02%
DAX 40	25,302.29	24.61	0.10%
Dow JONES (US)	51,850.55	195.60	0.38%
FTSE 100	10,713.95	57.67	0.54%
HKSE	24,345.22	74.02	0.30%
NASDAQ	27,245.90	120.27	-0.44%
Nikkei 225	67,777.52	1,253.40	-1.82%
NZX 50 Index	13,749.60	78.02	-0.56%
S&P 500	7,807.24	0.00	0.00%
S&P/ASX 200	8,783.90	0.70	0.01%
SSE Composite Index	3,800.86	3.62	0.10%